Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
With
Celgene Corporation
The purpose of this phase III study is to evaluate the clinical benefit of liso-cel for the treatment of r/r FL by comparing it to standard of care therapy in patients with r/r FL, with progression-free survival (PFS) as the primary endpoint.
The primary objective is to demonstrate superiority of the Liso-cel treatment strategy over standard of care (SOC) therapy with respect to progression-free survival (PFS) determined by independent review committee (IRC) based on the Lugano response criteria.
Participants randomized to Arm A (Standard of Care) will receive RCHOP, BR, or R2 based on investigator choice and this has to be determined prior to randomization.
Participants randomized to Arm B (Liso-cel treatment) will receive a single infusion CAR-positive viable T-cells.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have measurable disease.
Participants must have previously been treated with certain defined anti-cancer therapies and their disease must have come back or must have not responded to the previous or last treatment.
Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Participants that have histologically confirmed Follicular Lymphoma (FL) (Grade 1, 2, or 3a) corresponding to the most recent relapse prior to screening.
Participants that have Relapsed or refractory FL, as assessed by the Investigator.
Participants that have received at least one prior line and no more than three prior lines of systemic therapy including a combination of an anti-CD20 antibody and an alkylating agent.
You may not be if
Participants must not have any history of heart problems.
Participants must not have any bleeding disorders.
Participants must not have any Central Nervous System involvement by Follicular Lymphoma or other brain conditions.